On 3rdOctober 2019, PCT application titled “Means and methods for glycoprofiling of aprotein” (applicant Glycanostics, inventors Tomas Bertok and Jan Tkac) waspublished under publication number WO 2019/185515. This patent applicationcovers the main principles and company´s IP used during the diagnostic assaydevelopment.
Patent abstract: Thepresent invention provides magnetic carriers, anti-glycoprotein antibodies, theantigen binding portions thereof, one or more lectins, compositions, kits,methods and uses based thereon including uses in methods for glycoprofiling ofglycoproteins using lectins, e.g., in diagnostics of cancer. The magneticcarriers, anti-glycoprotein antibodies, the antigen binding portions thereof,one or more lectins, compositions, kits, methods and uses based thereon areapplicable to any glycoprotein.
ESET launched a prestigious ESET Science Award for exceptional scientists
Glycanostics successfully finished the first phase of SME Instrument
After receiving the prestigious “Seal of Excellence” on October 23, the next submission to the Horizon 2020 Programme, won a € 50 000 grant.
This project received the highest scores for its proposal in the extremely competitive evaluation process.
Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.
The application covering Glycanostics' diagnostic method is currently filed in two patent offices in Europe and Luxemburg.
Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.
The competition's objectives are to actively support innovative projects with high market potential
In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.
Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.